MedTrace Logo

Behavioral Activation for Smoking Cessation in PTSD

NCT01995123 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2020-04-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine whether behavioral activation as an adjuvant to standard smoking cessation treatment improves smoking cessation outcomes among veterans with PTSD relative to a comparably intense combination of standard smoking cessation treatment + health and smoking education. It is expected that behavioral activation will produce more successful results than health and smoking education when paired with standard smoking cessation treatment.

Conditions

  • Tobacco Dependence
  • PTSD

Interventions

BEHAVIORAL

Behavioral Activation Therapy

Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.

BEHAVIORAL

Health and Smoking Education

Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.

BEHAVIORAL

Standard Smoking Cessation Therapy

Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.

Sponsors & Collaborators

  • University of Wisconsin, Madison

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Jessica M Cook, PhD · William S. Middleton Memorial Veterans Hospital, Madison, WI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-08
Primary Completion
2019-03-29
Completion
2019-03-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01995123 on ClinicalTrials.gov